Ulrich Keilholz

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Alexander M.M. Eggermont, Stefan Suciu, Mario Santinami et al. · The Lancet · 2008 · 638 citations

Surgical Oncology, Medicine, Eortc 18991 +7

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Olivier Michielin, Alexander C. J. van Akkooi, Paolo A. Ascierto et al. · Annals of Oncology · 2019 · 606 citations · Full text

Dermoscopic Image, Melanoma, Cutaneous Melanoma +3

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Axel Hauschild, Sanjiv S. Agarwala, Uwe Trefzer et al. · Journal of Clinical Oncology · 2009 · 540 citations · Full text

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette et al. · The Lancet Oncology · 2015 · 386 citations

Neoadjuvant Therapy, Neck 1, Randomised Phase 3 +10